Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial

Article Abstract:

A randomized controlled trial is used to evaluate the effectiveness of pexelizumab, a humanized monoclonal antibody that binds the C5 component of complement, as an adjunct to percutaneous transluminal coronary intervention (PCI) in improving 30-day mortality from ST-elevation myocardial infarction (STEMI). The results have shown that the clinical trials of patients treated with primary PCI for STEMI mortality was low and unaffected by adminstration of pexelizumab.

Care and treatment, Mortality, Patient outcomes, Risk factors, Heart attack, Clinical report, Pexelizumab

---

Relationship of incorrect dosing of fibrinolytic therapy and clinical outcomes

Article Abstract:

An attempt is made to determine whether the association between incorrect dosing of altepase and adverse outcomes is related to cause and effect or to confounding. Results revealed that relationship between incorrect dosing and patient outcome in ASSENT-2 is primarily due to confounding factors rather than incorrect dosing itself.

United States, Complications and side effects, Tissue plasminogen activator

---

Similar abstracts:

• Abstracts: Guggulipid for the treatment of hypercholesterolemia: a randomized controlled trial. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol
• Abstracts: Effects of tolvaptan a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
• Abstracts: Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE)
• Abstracts: More scrutiny for dietary supplements? Antidepressants and pregnancy. Suicide caution stamped on Antidepressants
• Abstracts: Scientist set to decode influenza genome. Methods to detect circulating tumor DNA may help early diagnosis of cancer

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.